

The Technology Seminar Series Presents:

**“The Next Evolution in Biomarker
Interrogation: Advanced by NanoNeedles”**

Qimin Quan, PhD., CSO CO-Founder
Brendan Rickett, Business Development Manager



Thursday, November 17th, 2022

12:00 – 1:00 pm

**MEE 243 Charles Street Boston, MA, The Meltzer
Auditorium (3rd Floor) and Zoom**

<https://masseyeandear.zoom.us/j/583662273?pwd=TWJtUEV6ZTFUTzUzaWx5dXFmR2puQT09>

Meeting ID: 583 662 273

Passcode: 248969



Summary of talk:

MosaicNeedles: High-sensitivity, High-throughput Biomarker Quantification

Biomarkers are an integral part of diagnostics that drive the transition from the model of intervention to prevention. It is estimated by CDC that 70% of today's medical decisions are based on the laboratory test, which demands better sensitivity and specificity for preventive care. We have developed a high-sensitivity, large dynamic range and high-throughput protein quantification technology powered by label-free single molecule sensor – nanoneedles. More than 2 billion nanoneedles (MosaicNeedles™) are integrated on to a standard SBS plate and can be grouped into 96, 384 or 1536 formats, thus achieving ultra-high multiplexing levels. Each nanoneedle is a single molecule label-free sensor, thus, analyte concentrations in solution can be quantified by detecting single molecules in a digital fashion that reaches high sensitivity at fg/ml level. We envision researchers will use MosaicNeedle platform in the upstream discovery phase and then transfer to the downstream panel development by building customized and targeted panels of biomarkers of high interest that emerge from the discovery phase.

About Dr. Quan and Mr. Rickert:

Qimin Quan, PhD., Co-founder and Chief Scientific Officer, NanoMosaic, USA

Dr. Qimin Quan is co-founder and Chief Scientific Officer of NanoMosaic, a Boston-based biotechnology company to develop and leverage the power of nanoneedles for proteomics and multiomics. Prior to NanoMosaic, Dr. Quan is a PI and Rowland Fellow at Rowland Institute at Harvard University.

Brendan Rickert, MS, MBA, New England Business Development Manager, NanoMosaic, USA

Brendan joined NanoMosaic in June of 2022 as the New England Business Development Manager. Prior to joining NanoMosaic, Brendan held the same position at IsoPlexis. His passion for helping people is his main focus and believes strongly that the insights NanoMosaic's platform delivers is important to researchers like yourself to make the leap in your research. When Brendan isn't working he enjoys building Legos and will never turn down ice cream.

